For more information on this report please contact [email protected] (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1141/Medical-Devices-Industry-and-Market-Prospects-2013-2023
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Figure 6.11 Other Neuromodulation Devices: Revenue Forecast ($bn), 2012-2023
Figure 6.12 Neuromodulation Devices: Market Shares (%) by Sector, 2012
Figure 6.13 Neuromodulation Devices: Market Shares (%) by Sector, 2017
Figure 6.14 Neuromodulation Devices: Market Shares (%) by Sector, 2023
www.visiongain.com
Contents
Abbott Laboratories
Angiotech Pharmaceuticals
Apnex Medical Inc
Association of Indian Medical Device Industry (AIMED)
Baxter International
Becton Dickinson & Co
Biosensors International
Biotronik SE & Co
Boston Scientific
Brazilian National Agency for Sanitary Surveillance (ANVISA)
Bristol Myers Squibb
CeloNova BioSciences Inc
Center for Devices and Radiological Health (CDRH) [US]
Central Drug Standard Control Organisation (CDSCO) [India]
Cerbomed
Cerebral Rx
China Food and Drug Administration (CFDA)
ClearStream Technologies
Cochlear Ltd.
Conor Medsystems Inc
Cordis Corporation
CVRx Inc
Cyberonics Inc.
DePuy Inc
Economic Committee for Medical Products [France]
ElectroCore
EnteroMedics Inc
Ethicon Endo-Surgery Inc
Eucomed
Organisations Mentioned in this Report
www.visiongain.com
Contents European Commission (EC)
Food & Drug Administration (FDA) [US]
GE Healthcare
Gemeinsame Bundesausschuss (G-BA) [Germany]
GlaxoSmithKline (GSK)
Global Harmonisation Task Force (GHTF)
Guidant Corporation
Impulse Dynamics
ImThera Medical Inc
Insightra Medical
Intelect Medical Inc
International Medical Device Regulators Forum (IMDRF)
International Neuromodulation Society (INS)
IntraPace Inc
Johnson & Johnson (J&J)
JW Medical Systems
KangHui Medical
Kiestra Lab Automation
Labcoat Ltd
Lupin Pharmaceuticals Inc
Medison Co Ltd
Medical Device Regulatory Authority (MDRA) [India]
Medtronic Inc
MetaCure Inc
MiCell Technologies Inc
Ministry of Health, Labour, and Welfare (MHLW) [Japan]
MIV Therapeutics Inc
National Epilepsy Foundation [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
NeuroPace Inc
Northstar Neuroscience Inc
www.visiongain.com
Contents Novartis
OrbusNeich
Ortho-Clinical Diagnostics Inc
Patient-Centered Outcomes Research Institute (PCORI) [US]
Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
Pfizer
Philips Healthcare
Roszdravnadzor [Russia]
Roche
Samsung
Sanofi-aventis
Servizio Sanitario Nazionale (SSN) [Italy]
Siemens Healthcare
Sistema Unico de Saude (SUS) [Brazil]
St Jude Medical
St. Michael’s Hospital, Toronto, Canada
Stryker Corporation
Synthes
Terumo Medical Corporation
Teva Pharmaceutical Industries Ltd
Third Wave Technologies Inc
Transneuronix Inc
Trauson Holding
United Nations (UN)
United State Patent and Trademark Office (USPTO)
UCB Biopharma
Vitality Devices
World Health Organisation (WHO)
Page 39
www.visiongain.com
Medical Devices Industry and Market Prospects 2013-2023
3.1.2.1 Johnson & Johnson: Largest Market Share in the Medical Device
Sector Johnson & Johnson had the largest market share in the medical devices sector in 2012. J&J’s
medical devices division generated total global revenues of $27.4bn in the year to 1 January 2013.
This $27.4bn accounted for 40.8% of J&J’s global net sales and was also equivalent to 8.5% of the
medical devices global sales for 2012. The orthopaedic devices arm of the business remains the
highest grossing submarket for J&J’s medical devices portfolio with sales of $7.8bn in 2012 (Table
3.3, Figures 3.2 and 3.3). This represents a 34.3% increase on its 2011 net sales figure.
Table 3.3 Johnson & Johnson Medical Devices and Diagnostics: Revenue
($bn) and Revenue Shares (%) by Franchise, 2012
Business Segment Revenue ($bn) 2012 Revenue Share (%) 2012
Orthopaedics 7.8 28.4Surgical care 6.5 23.6Vision care 3.0 10.9Diabetes care 2.6 9.5Speciality Surgery 2.5 9.2Diagnostics 2.1 7.5Cardiovascular care 2.0 7.2Infection Prevention/other 1.0 3.5Total medical devices sales 27.4 100.0
Source: J&J 2013, Visiongain 2013
Page 100
www.visiongain.com
Medical Devices Industry and Market Prospects 2013-2023
4.4 Opportunities
4.4.1 An Aging Global Population The over-65 age group is an important demographic group in the medical device industry. The
future fate of the medical device industry will be largely determined by whatever happens to the
people within this demographic. A large proportion of the products in the medical device market are
targeted at the over-65s. This is especially true for neurological and orthopaedic devices, where
many of the conditions treated using medical devices is most prevalent in the over-65s.
With reports estimating the global over 65 population to reach 1billion by 2030, the aging
population globally provides a strong opportunity to expand revenue base in a number of device
sectors. The UN estimates the global over-65 population to have tripled over the last 50 years. It
also estimates this number to increase by more than 50% in the next four decades to reach 418m
by 2050 in developed regions of the world. Moreover, the UN estimates that, in developing
countries, the over-65 population will reach 1.6bn by 2050, representing a third of the total
population in these countries.
While an aging population will expand the market for devices targeted at diagnosing and treating
age-related problems, other therapeutic needs will become present in younger generations. It is
expected that growth in the orthopaedic market will also be driven by younger patients undergoing
surgery. Research published in 2010 found that the average of patients undergoing knee
replacement in the US dropped by two years from the early 1990s to the early 2000s. Such trends
will continue to drive the orthopaedic devices market from 2012 onwards, visiongain concludes.
4.4.2 Personalised Medicine Providing Growth Opportunities The issue of tailored medicine is currently a growing area in the medical devices R&D sector.
Personalised medicines represent a good opportunity to boost the total revenue in the medical
devices sector, especially in the biomarkers submarket where researchers are currently reporting
positive prospects for the future use of biomarkers in the diagnosis of various conditions.
Personalised medicine provides two key opportunities in the medical devices market. The first of
this is that therapeutic devices can be tailored to individual patient needs. An example of
personalised medicine is the December 2012 release of crizotinib by Pfizer for the treatment of
lung cancer. Furthermore, neuromodulation devices have already been designed, tested, and
approved using this technology. Medtronic’s RestoreSensor, given CE approval in 2010, uses
Page 129
www.visiongain.com
Medical Devices Industry and Market Prospects 2013-2023
6. The Neurological Device Market 2013-2023 The neurological sector covers devices that interact with, or are used to treat the central nervous
system. A number of neurological disorders are treated with neurological devices, including
neurodegenerative diseases such as Alzheimer’s and Parkinson’s. For the purposes of this report,
neurological devices have been categorised as the following:
• Neuromodulation devices. By far the largest subsector, this covers devices used to
stimulate the central nervous system in the treatment of conditions ranging from
Parkinson’s disease to major depressive disorder. The three main types of
neuromodulation are:
• Spinal Cord Stimulation (SCS)
• Deep Brain Stimulation (DBS)
• Vagus Nerve Stimulation (VNS)
• Neurovascular devices, such as neurovascular catheters and neurovascular stents. The
stents are used to open arteries in the neck or brain that have closed due to
atherosclerosis. Neurovascular stents are more flexible than coronary stents, discussed in
chapter 5.
• Cerebrospinal fluid devices. This includes devices used to remove fluid that has
accumulated in the ventricles of the brain, a condition known as hydrocephalus.
• Other neurological devices include those used in brain biopsies, liquid embolics and
detachable units, both of which are used for treating aneurysms.
6.1. Neurological Devices: Market Overview The neurology devices market is one of the fastest growing sectors of the global medical devices
market, owing to the ongoing major unmet clinical need in the treatment of neurological disorders.
This sector covers devices that interact with, or are used to treat, diseases of the central,
peripheral and autonomic nervous system, including degenerative diseases such as, Alzheimer’s
and Parkinson’s. The sector generated sales of $5.2bn in 2012, representing 1.6% of the global
medical devices market (Figure 3.1). With continuous improvements in the device technology, the
neurology devices market is set to witness double digit growth rate in the next decade.